Recent Event Highlights: FDA Approves Lupus Drug From Human Genome, Glaxo - Wall Street Journal, HGSI Human Genome Sciences Benlysta Approval Impact Personal Level Pt 1, Human Genome Sciences Receives FDA Approval for Benlysta Lupus Drug (VIDEO) Part 2, Oh So Close to Hitting the Throttle: VICL, HGSI, and QPSA on the Radar - Small Cap Network, SHARES OF DENDREON RANK RELATIVELY HIGH IN TERMS OF UPSIDE POTENTIAL IN THE ... - Zacks.com, Midday Unusual Options Activity Update - HGSI, S, TIVO, HRB, BHP, RSH - The Options Insider, and 231 more...
Created by dipity on Apr 30, 2009
Last updated: 03/10/11 at 12:08 AM
Hgsi has no followers yet. Be the first one to follow.
www.stockmarketfunding.com Human Genome Sciences Receives FDA Approval for Benlysta Lupus Drug (VIDEO) Part 2 Human Genome Sciences Receives FDA Approval for Benlysta Lupus Drug (VIDEO) FDA Approval Decision for Benlysta. Human Genome halted, news pending material information T1 Halt. "HGSI" "Human Genome Sciences" "HGSI Benlysta" "benlysta HGSI" "lupus drug" "drug for lupus" "FDA approval" "HGSI Halted" "HGSI news" "news HGSI" "benlysta fda" "hgsi stock" "stock hgsi"
Excerpt
...prices, however, are much more muted and currently(2) suggest only a $4.00 upside move which, on a positive scenario, places HGSI’s share price around $30. I tend to believe the option implied prices over analyst estimates. I combined the butterfly spread...
Source Info
Seeking Alpha
http://seekingalpha.com/article/257114-trading-human-genome-sciences-pending-fda-decision?source=feed
Excerpt
...to jump in for the long term. Disclosure: I have no positions in any stocks mentioned, but may initiate a long position in HGSI over the next 72 hours. Be the first to comment on this article I'm VFC. After years of blowing through spare money and then starting...
Source Info
ETF Investor
http://seekingalpha.com/article/256707-is-this-the-week-for-human-genome-s-benlysta?source=feed
www.StockMarketFunding.com HGSI RBC Capital Markets Healthcare Conf Part 1 Benlysta FDA Date 3 Human Genome Sciences(HGSI_): FDA drug approval decision date for Benlysta in lupus. Video on: HGSI Human Genome Sciences FDA Panel Review Selling Rumors Speculation Benlysta Drug Approval Lupus...
www.StockMarketFunding.com Massive Institutional Buying HGSI 500000 Share Big Block Trades. All Eyes on Human Genome Sciences Benlysta FDA Decision Pt 1. BENLYSTA® FDA Approval Recommended by Advisory Committee; PDUFA Target Date for FDA Decision Extended to March 10, 2011 HGSI Human...
Excerpt
...On average, analysts predict that Human Genome Sciences will post $-0.36 EPS next quarter. Shares of Human Genome Sciences (HGSI) traded up 0.52% during mid-day trading on Tuesday, hitting $25.16. Human Genome Sciences has a 52 week low of $20.56 and a 52...
Source Info
American Banking and Market News
http://feedproxy.google.com/~r/AmericanBankingNews/~3/paiQytXSdls/
www.SMFProTrader.com All Eyes on Human Genome Sciences Benlysta FDA Decision Pt 1. BENLYSTA® FDA Approval Recommended by Advisory Committee; PDUFA Target Date for FDA Decision Extended to March 10, 2011 HGSI Human Genome Sciences FDA, HGSI Human Genome Sciences FDA Human Genome Sciences...
www.StockMarketFunding.com Human Genome Sciences HGSI Physcian Q on FDA Benlysta Approval Webcast of Presentation at Leerink Swann Conference Part 3. Video on: hgsi "hgsi stock" Human Genome HGSI Physcian Q/A FDA Benlysta Approval Webcast Leerink Swann Conference trading stocks "stock market"...
www.StockMarketFunding.com Human Genome Sciences HGSI Physcian Q on FDA Benlysta Approval Webcast of Presentation at Leerink Swann Conference Part 2. Video on: hgsi "hgsi stock" Human Genome HGSI Physcian Q/A FDA Benlysta Approval Webcast Leerink Swann Conference trading stocks "stock market"...
www.StockMarketFunding.com Human Genome Sciences Institutional Investors Increase Shares in HGSI. Institutional Investors Update for HGSI Human Genome Sciences Inc. GENZ Genyzme 2nd Largest Biotech Buyout in History. Sanofi Buys Genzyme for Over $20 Billion. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Leerink Swann Conference. "Top biotech stock" to be HGSI or a possible "HGSI takeover" as institutional investors and traders continue to add to their current position. "Biotech sector" update on HGSI . Genzyme (GENZ) disappointed on both its bottom and top line, but the company has agreed to be purchased by Sanofi-Aventis (SNY) for $74 per share plus a Contingent Value Right. Institutional Investors Increase Shares in HGSI
www.StockMarketFunding.com Human Genome Sciences, Inc. (NASDAQ HGSI) 13th Annual BIO CEO and Investor Conference Part 1 Human Genome Sciences HGSI Leads Biotech Sector Higher SPA FDA Agreements. Human Genome Sciences Goes on a Massive Hiring Spree Ahead of the FDA Approval Date Breaking News....
www.StockMarketFunding.com Human Genome Sciences, Inc. (NASDAQ HGSI) 13th Annual BIO CEO and Investor Conference Part 1 Human Genome Sciences HGSI Leads Biotech Sector Higher SPA FDA Agreements. Human Genome Sciences Goes on a Massive Hiring Spree Ahead of the FDA Approval Date Breaking...
www.StockMarketFunding.com HGSI Big Block Purchase 400000 on the Closing Bell. Live stock market trading video and human genome sciences, huge purchase on the closing Bell 400000 shares one million-dollar purchase. Institutional investors move in scooping up, adding to their share. We saw shares of human genome science move higher on the heels of negative move for Cisco and the tech sector bucking the overall trends in stock indexes. We'll see if tomorrow, human genome sciences HGSI will trade higher in break above the $26 handle. We'll be updating people on the weekly long-term technical analysis of human genome sciences and the breakout been listed drug approval and denial by the FDA in the coming weeks ahead.
www.StockMarketFunding.com Human Genome Sciences "HGSI" Benlysta Development and Stock Trading Update. StockMarketFunding.com Biotech Release Update Human Genome Sciences HGSI Mario Marciano has been covering biotech start ups for over 20 years. The last biotech trades he was involved in include DNDN, HGSI, MLMN, OSIP, DNA, GENZ, CELG, AMLN, AMGN, BIIB, MRK, and LLY. Over the last 12 years he's had his eyes on HGSI Human Genome Sciences. Mario has followed the Benlysta trials and recent trading action in HGSI. StockMarketFunding.com will be conducting a special audit on HGSI Stock and how the big players on Wall Street already own the stock with 92.8% Institutional Ownership. We will also look at why and what Wall Street has done to manipulate HGSI's company stock price in recent months. The rumors that have been wide spread and StockMarketFunding.com has covered all the trades through our live trading videos to prove how Wall Street can manipulate investors with untrue facts, fabricated headlines and blog posts. Mario has clearly stated that these companies spend millions of dollars in research and development and lately HGSI had a vote of 13-2 approval for a new drug for lupus. The final extension date for possible approval 3-10-2010 will make a major breakthrough if approved. We believe there will be many more new developments and this will lead to HGSI becoming a major player in biotechnology which will lead to HGSI becoming a new 21st century biotech leader in ...
www.StockMarketFunding.com Human Genome Sciences (HGSI) Technical Analysis History 2011 Biotech Leader Pt 2. Human Genome Sciences FDA Panel Review resulted in an extension to March of 2011. Benlysta Lupus Drug "Suicide Rate" Risks were a concern but we believe these will not prevent from the FDA approving Benlysta. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst or possible Market Manipulation? We saw big increases in institutional ownership as T Rowe Price increased it's share count by 5.5 million shares as of 9 November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Draft Guidance for Industry: Suicidality -- Prospective Assessment of Occurrence in Clinical Trials, regarding Overview of the FDA background materials for BLA# 125370, Benlysta (belimumab) lyophilized powder for intravenous infusion, at a dose of 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter, for reducing disease activity in adult patients with active, auto ...
www.StockMarketFunding.com Human Genome Sciences (HGSI) Technical Analysis History 2011 Biotech Leader Pt 1. Human Genome Sciences FDA Panel Review resulted in an extension to March of 2011. Benlysta Lupus Drug "Suicide Rate" Risks were a concern but we believe these will not prevent from the FDA approving Benlysta. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst or possible Market Manipulation? We saw big increases in institutional ownership as T Rowe Price increased it's share count by 5.5 million shares as of 9 November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Draft Guidance for Industry: Suicidality -- Prospective Assessment of Occurrence in Clinical Trials, regarding Overview of the FDA background materials for BLA# 125370, Benlysta (belimumab) lyophilized powder for intravenous infusion, at a dose of 10 mg/kg at 2-week intervals for the first 3 doses and at 4-week intervals thereafter, for reducing disease activity in adult patients with active, auto ...
www.StockMarketFunding.com After hours we saw huge purchases in HGSI as a purchase hit the tape 426138 shares at $25.07 which is well above the average on-the-close volume. This was followed by a massive 400000 purchase at $25.07 which represents a $10 Million purchase. We will continue to watch HGSI and break updates as they develope in the biotechnology sector. We've seen increased volatility in HGSI as the intraday trading range has expanded to the upside hitting a high of $26.25 yesterday then the sellers moved in taking it down to an intraday low today of $24.81. We saw 2759697 shares traded with no new news.
www.StockMarketFunding.com HGSI Human Genome Sciences Special FDA Dec 9th Approval Date Pt 1. Human Genome Sciences And Glaxosmithkline Announce Vote Of FDA Advisory Committee To Recommend Approval Of Benlysta® For Systemic Lupus Erythematosus. Human Genome Sciences, Inc. (Nasdaq HGSI) and GlaxoSmithKline PLC (GSK) today announced that the Arthritis Advisory Committee of the US Food and Drug Administration (FDA) has voted 13 to 2 to recommend that the FDA approve BENLYSTA® (belimumab) for the treatment of autoantibody-positive patients with active systemic lupus erythematosus (SLE). The FDA Arthritis Advisory Committee is convened to provide the FDA with independent expert advice on a broad range of issues related to rheumatology drug products. The committee provides non-binding recommendations for consideration by FDA, with the final decision on approval made by FDA. The FDA has assigned BENLYSTA a Prescription Drug User Fee Act target date of December 9, 2010. Belimumab is an investigational drug and the first in a new class of drugs called BLyS-specific inhibitors. HGS and GSK are developing belimumab under a definitive co-development and co-commercialization agreement entered into in 2006. Under the agreement, HGS has responsibility for conducting the belimumab Phase 3 trials, with assistance from GSK. The companies will share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialized under the current agreement ...
www.StockMarketFunding.com Human Genome Sciences Benlysta Drug Approved by FDA Panel for Lupus (HGSI). Human Genome Sciences Benlysta Drug Approved for Lupus HGSI. FDA Approves Benlysta Human Genome Drug (HGSI) for Lupus Patients 50 Year Healthcare Development. Human Genome Sciences Benlysta Drug Approval HGSI FDA Panel. Tomorrow is the big day! We finally see how Human Genome Sciences Blockbuster Hopes on Lupus Drug Benlysta Pans Out based on Human Genome Sciences Benlysta® "FDA Panel Endorses a Drug to Treat Lupus" FDA Panel votes in favor of Benlysta stock expected to trade higher on Wednesday 17, 2010. FDA panel backs first new lupus drug in 50 years - Health News. Federal health experts on Tuesday voted in favor of the first new drug to treat Lupus in over 50 years. FDA Panel Recommends Approval Of Human Genome, Glaxo Lupus Drug. FDA Panel Endorses a Drug to Treat Lupus
Excerpt
...of HGSI Human Genome Sciences rose sharply Monday November 15, 2010 as shares rose to $26 in after hours trading on 387.8% above average trading. for November 15th, 2010. Shares of HGSI Human Genome Sciences rose sharply Monday November 15, 2010 as shares...
Source Info
Figure/Speed Skating
http://www.suite101.com/content/human-genome-sciences-stock--options-trading-analysis-hgsi-a309376
Excerpt
...regarding the failure of a major clinical trial of HGSI to hedge funds which then sold approximately six million shares of HGSI during December 2007 and January 2008, while in possession of that material non-public information. On January 23, 2008, HGSI publicly...
Source Info
PR Newswire
http://www.prnewswire.com/news-releases/if-you-bought-shares-of-human-genome-sciences-inc-hgsi-in-december-2007-or-january-2008-you-may-have-a-substantial-claim-for-damages-against-large-hedge-funds-managed-by-morgan-stanley-108238189.html
www.StockMarketFunding.com Human Genome Sciences Trading Video HGSI Sell Order GTC Profit Objective Pt 1 HGSI Jan 2011 30 Calls 5000 Contracts Purchase. Biotech Stock Alert Equity & Options Volume Activity Alert HGSI (Human Genome Sciences). HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ: HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus ...
www.StockMarketFunding.com HGSI Jan 2011 30 Calls 5000 Contracts Purchase. Biotech Stock Alert Equity & Options Volume Activity Alert HGSI (Human Genome Sciences). HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ: HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus ...
www.SMFStocks.com Rare Video Footage Exclusive Interview StockMarketFunding.com CEO Mario Marciano Stock Market Mastermind! http (HGSI) Human Genome Sciences Benlysta Drug Approval for Lupus Patients. New Break through in Human Genome Sciences Benlysta drug approval for lupus patients. Will the Benlysta FDA Approval Come? We believe so at SMF and we will cover the pros and the cons of the HGSI new drug and benefits to humanity. We will take a look at one of the most positive developments in "biotechnology" in the past 50 years. We have highlighted HGSI and the longer term trends relative to the current drug developments. BENLYSTA is an investigational human monoclonal antibody drug. It is the first in a new class of drugs called BLyS-specific inhibitors that recognize and inhibit the biological activity of B-lymphocyte stimulator, or BLyS, which was discovered by HGS in 1996. We and GlaxoSmithKline (GSK) are developing BENLYSTA under a co-development and commercialization agreement entered into in 2006. In lupus, rheumatoid arthritis and certain other autoimmune diseases, elevated levels of BLyS are believed to contribute to the production of autoantibodies -- antibodies that attack and destroy the body's own healthy tissues. BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). In June 2010, HGS and GSK submitted regulatory applications seeking approval to market BENLYSTA in the ...
www.StockMarketFunding.com Biotech Stock Alert Equity & Options Volume Activity Alert HGSI (Human Genome Sciences). HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ: HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus ...
www.SMFProTrader.com Biotech Stock Alert Equity & Options Volume Activity Alert "HGSI" (Human Genome Sciences). HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ: HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus ...
A discussion of recently released information on Benlysta.
www.StockMarketFunding.com Biotech Stock Alert Equity & Options Volume Activity Alert HGSI (Human Genome Sciences). HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ: HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus ...
www.StockMarketFunding.com HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Draft Guidance for Industry: Suicidality ...
www.StockMarketFunding.com HGSI Human Genome Sciences FDA Panel Review Selling off on Rumors and Speculation on Benlysta Lupus Drug "Suicide Rate" Risks. Human Genome Sciences (NASDAQ HGSI) opened at $26.00 after trading as high as $29.50 in "pre market trading". today, the stock has hit a low of $23.68 and a high of $26.24 3.7X High Trader volume as over 10 million shares of trading so far today with another 1 hour and 50 minutes of trading remaining. The stock is down 9.86% as we wait to see how the results for Benlysta are received by the FDA. The "wall street" media hypsters are at it again indicating that the HGSI FDA Panel Review results were "surprising" and we believe there is no additional information in the FDA Panel Review that would have us change our stance on the equity. Human Genome Sciences Lupus Drug FDA Program Schedule Assuming the Worst Market Manipulation? Human Genome Sciences Pre Market Gap FDA Benlysta News Pending (HGSI). HGSI had increased price action and volatility as the stock spiked to $29.48 in pre market trading as the FDA released it's 133 page FDA Briefing Information, Belimumab (BENLYSTA), for the November 16, 2010 Meeting of the Arthritis Advisory Committee which addressed Guidance for Industry: Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Guidance for Industry: Lupus Nephritis Caused by Systemic Lupus Erythematosus -- Developing Medical Products for Treatment, Draft Guidance for Industry: Suicidality ...
Excerpt
Human Genome Sciences (HGSI - option chain) stock is trading lower today after briefing materials for an FDA advisory panel were released that questioned whether the benefits of Benlysta, a proposed lupus treatment from HGSI and GlaxoSmithKline (GSK),
Source Info
Blogging Stocks
http://www.pheedcontent.com/click.phdo?i=1a648de0f992938b2761e439664d7c3d
www.StockMarketFunding.com HGSI Huge Stock Trade off the Bottom Opening Bell Wall St. Watch how SMF Pro Traders get entries at the low end as Human Genome Sciences moves higher. http Human Genome Volume Alert Huge Buying and Trading Breakout Going into Benlysta FDA Announcement Part 2. (HGSI) Human Genome Sciences Stock & Options Trading Analysis for November 15th, 2010. Shares of HGSI Human Genome Sciences rose sharply Monday November 15, 2010 as shares rose 9.66% to $26 in after hours trading on 387.8% above-average trading volume. We saw a short squeeze going into the close as shares have come under recent price volatility and price movement. Shares of HGSI rose off the intraday lows of $24.28 to an intraday high of $25.93 as investors and traders a like scooped up big blocks of stocks and options throughout the trading day. Today with the 4th trading day of 300%+ above average trading volume totaling 46884145 shares over the past 4 trading days. That number represents 24.925% of the float according to Yahoo Finance. We saw 5000 share print on the January 30 Call right on the opening bell and the closing volume is currently 11962107 and we'll continue to mornitor the after hours volume and price action as shares settle. We'll see what type of coverage HGSI gets on CNBC and with Jim Cramer or any of the Fast Money traders talk about the stock. Guy Adami has been bullish on the stock for several weeks. We'll continue to closely the trading activity. StockMarketFunding ...
www.StockMarketFunding.com Human Genome Sciences HGSI Special Biotech Future Video. SMF Reiterates Strong Buy Rating on Human Genome (HGSI). HGSI Big Block Trades Huge Buys Going into the Close. HGSI Special Biotech Future Video SMF Reiterates Strong Buy Rating Human Genome trading stock stocks "the stock market" biotechnology "biotech stocks" drug drugs "drug companies" pharmaceutical Benlysta lupis "lupis drug" "drug lupis"
www.StockMarketFunding.com Predictions in BioTech Not Stock HGSI prior to the "FDA Approval of Benylsta". What's the next Big Biotech Stock? HGSI Human Genome Sciences "The Next Big Cap BioTech Stock" HGSI Human Genome Sciences Next Big Cap BioTech Stock
www.StockMarketFunding.com 11-6-2010 Human Genome Sciences HGSI Risk Management Trading with Position Management Planning. Human Genome Benlysta FDA Panel Preview. Human Genome pins blockbuster hopes on lupus drug. The US Food and Drug Administration advisory panel meets Nov. 16 and will vote whether or not to recommend Benlysta's approval as a treatment for lupus, an autoimmune disease that has gone 50 years without a new, effective therapy for affected patients. he FDA is expected to post online its own review of Benlysta on Friday, Nov. 12, in advance of the FDA panel meeting. SMF Pro Traders have been putting together this trade. Lupus drug Benlysta could be a boon for HGS and GSK. StockMarketFunding will provide live updates during the Benlysta FDA panel on Nov. 16. Will the FDA panel recommend Benlysta's approval? Yes or No? Lupus has proven intractable to treatment with new drugs for years, yet Human Genome Sciences managed to conduct two, large phase III studies of Benlysta, each with positive results. Lupus patients are desperate for a new drug. Individual investors are wading back into the US stock market. That ought to make über-bulls think twice.Positive forces including strong corporate earnings, improving economic data and more bond buying by the Federal Reserve have fueled a 17% rally in the Standard & Poor's 500-stock index since late August. The market has now punched through its prior 2010 highs, set in April, to reach levels last seen in 2008 before the ...
www.StockMarketFunding.com Options Trading Strategies HGSI $10 Put SMF MMT Risk Management Training. Live 11 options trading video for SMF MMT Traders on HGSI $10. We'll over the "options entry" pricing model for SMF MMTs and other "wall street traders"
www.StockMarketFunding.com Stock Market Trading HGSI Human Genome Sciences Huge Trading Profits Entry & Exits Off the Bottom Trade HGSI Human Genome Sciences. Huge Trading Profits Entry & Exits Off the Bottom Trade. Live stock market trading video where we break down the intraday trading...
Human Genome Sciences (NASDAQ:HGSI) and its partner Novartis AG (NYSE:NVS) announced Tuesday that they would stop pursuing US regulatory approval of their joint-research in a drug, Zalbin, meant for the treatment of Hepatitis C. The companies made the announcement after receiving a letter from the US Food and Drug Administration regarding the product's prospects. Human Genome had already announced earlier this year that it didn't expect Zalbin to win FDA approval, citing dosage concerns. SmarTrend is bullish on shares of Human Genome Sciences andour subscribers were alerted to buy on July 13, 2010 at $25.14. The stock has risen 20.1% since the alert was issued. SmarTrend is bullish on shares of Novartis and our subscribers were alerted to buy on June 10, 2010 at $47.16. The stock has risen 22.5% since the alert was issued.
www.StockMarketFunding.com Money Flows into Biotech Closing Bell on "Wall Street" BIG BLOCK Trade Financial Market Update Money Flowing into Biotech 397000 shares big block trade on HGSI at 4:00 PM $29.79 for total "money flow" of $11829579.21 "stock trade". HGSI Real Time: 29.77 1.04 (3.62%) 3:59PM EDT Human Genome Sciences Trading Higher on 1.3x Above-Average Volume. Biotechnology company Human Genone Sciences Nasdaq (HGSI). Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease. Human Genome Sciences Research. The stock was downgraded and punished "Human Genome Sciences (NASDAQ:HGSI) was downgraded to Market Perform from Outperform at Bernstein" and we told people in our videos that it was time to get net long the stock and we were upgrading the future prospects for the stock. Now the stock is trading higher on 30% above-average volume and we're doing quite well on our propreitary options trades.
www.StockMarketFunding.com BIG BLOCK Trade Financial Market Update Money Flowing into Biotech 100000 shares big block trade on HGSI at 3:27 PM $29.75. Human Genome Sciences Trading Higher on 1.3x Above-Average Volume. Biotechnology company Human Genone Sciences Nasdaq (HGSI). Human Genome Sciences is an emerging pharmaceutical company with the mission to predict, prevent, detect, treat and cure disease. Human Genome Sciences Research. The stock was downgraded and punished "Human Genome Sciences (NASDAQ:HGSI) was downgraded to Market Perform from Outperform at Bernstein" and we told people in our videos that it was time to get net long the stock and we were upgrading the future prospects for the stock. Now the stock is trading higher on 30% above-average volume and we're doing quite well on our propreitary options trades.
www.StockMarketFunding.com Understanding Stock Market Trading Strategies Bid Price Manipulation (HGSI). Watch this live premarket trading video on HGSI and how we show how market makers and traders walk up the bid to manipulate the price during light volume sessions. A quick and simple...
www.StockMarketFunding.com How to Trade Huge Stock Trade Big Block Purchase on Biotechnology Stock "HGSI" 151200 shares were bought at $29.05 the purchase totaled $4392360. NASDAQ Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at UBS Healthcare Conference Law Legal Issues Health Personal Finance Business Economy Pharma Bio-tech Editors Pick. These Are the Top 10 Pharma Underperform Calls. Wrap: S&P 500, , WYNN sell off HGSI video. Health Care Stocks to Heal Your Portfolio? HGSI, DNDN, and other Stocks to Play Biotech. Coverage initiated on Human Genome by Stifel Nicolaus Stock Market Talk Radio Show www.blogtalkradio.com Follow us on Twitter: www.twitter.com Follow us on Facebook: www.facebook.com Free Trial Signup onlinetradinginvesting.eventbrite.com Video Alert Signup http Trading Community (Free to Join) www.DailyStockCharts.com
www.StockMarketFunding.com How to Trade Closing Bell Stock Market Trading HGSI Double Top Highs Buying Dips. "Live Trade" Watch our traders and the trends online stock trading video and technical analysis of stock trends. Online Trading Platform trading analysis for our traders, stock trading...
www.StockMarketFunding.com HGSI Human Genome Sciences Stock Trading Video Wholesale Entry. Watch the Live Stock Market Trading Action in this video as SMF Pro Traders get the best price on the trade and wait for their entries as stocks have been pulling back all day.
www.StockMarketFunding.com HGSI Human Genome Sciences Stock Trading Video Wholesale Entry. Watch the Live Stock Market Trading Action in this video as SMF Pro Traders get the best price on the trade and wait for their entries as stocks have been pulling back all day.
www.StockMarketFunding.com Stock Market Technical Analysis Human Genome (HGSI) Monthly Chart Bullish Breakout Human Genome Sciences Bullish "Options Activity" $1 Million in options contracts purchased at the $30 Strike Price Weekly Chart Trend Analysis Video News & HGSI Trend Commentary. It's not lupus. It's never lupus." The words of Dr. Gregory House in the hit TV drama House MD probably did more to burn the complex autoimmune disease on the public consciousness than any medical awareness campaign.But there's a serious point While frequently put forward, a diagnosis of lupus rarely seems to turn out correct. And despite some very bullish forecasts, decisions on deal making and financing have so far been taken almost blindly because no one really knows just how large the lupus market is, or how big it could become in future.This could soon change. On November 16, Human Genome Sciences Inc. and GlaxoSmithKline's Benlysta will be reviewed by a US FDA advisory committee, and a positive verdict should pave the way to it becoming the first new treatment for lupus in 50 years. This, in turn, could spur deal interest in a number of companies developing earlier-stage projects, such as Sweden's Active Biotech, Germany's Biotest, the French micro cap Neovacs and private US start-up Argos Therapeutics Inc.Meanwhile, key projects that have already been licensed to large partners, such as Zymogenetics Inc's atacicept, Trubion Pharmaceuticals Inc's SBI 087 and ImmuPharma's Lupuzor ...
Excerpt
...a final decision at the FDA won an accelerated regulatory review. Human Genome Sciences will have... Human Genome Sciences (HGSI) is fast becoming a favorite target of put players. Bearishly oriented option volume has ramped up to twice the norm so far... ...
Source Info
NewsPlurk
http://feedproxy.google.com/~r/npusm/~3/KhrijjQDik8/lupus-drug-benlysta-belimumab-priority.html
Excerpt
...Genome Sciences, Inc. (HGSI) received a huge boost when its potential blockbuster drug candidate Benlysta was granted priority review status by the US Food and Drug Administration (FDA). Benlysta, co-developed by Human Genome and GlaxoSmithKline plc (GSK),...
Source Info
Benzinga.com
http://www.benzinga.com/10/08/437865/priority-review-for-hgsis-benlysta-analyst-blog
Excerpt
...200-day moving average. This closely watched trendline has created turbulence for the shares since early May. At last check, HGSI is up 0.5%, bucking a bearish trend in the broader equities market. Traders are cheering a report that the Food and Drug Administration...
Source Info
SchaeffersResearch.com
http://www.schaeffersresearch.com/commentary/trading_floor_blog.aspx?c=tfbfeed&blogid=101805&single=true
Update Sources